- Home
- RNAZ vs FTFT Comparison
RNAZ vs FTFT Comparison
Compare RNAZ & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- FTFT
- Stock Information
- Founded
- RNAZ 2016
- FTFT N/A
- Country
- RNAZ United States
- FTFT United States
- Employees
- RNAZ N/A
- FTFT N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- FTFT Business Services
- Sector
- RNAZ Health Care
- FTFT Consumer Discretionary
- Exchange
- RNAZ Nasdaq
- FTFT Nasdaq
- Market Cap
- RNAZ 7.2M
- FTFT 6.2M
- IPO Year
- RNAZ 2021
- FTFT N/A
- Fundamental
- Price
- RNAZ $8.08
- FTFT $0.24
- Analyst Decision
- RNAZ Strong Buy
- FTFT
- Analyst Count
- RNAZ 1
- FTFT 0
- Target Price
- RNAZ $20.00
- FTFT N/A
- AVG Volume (30 Days)
- RNAZ 4.3M
- FTFT 320.7K
- Earning Date
- RNAZ 03-31-2025
- FTFT 04-15-2025
- Dividend Yield
- RNAZ N/A
- FTFT N/A
- EPS Growth
- RNAZ N/A
- FTFT N/A
- EPS
- RNAZ N/A
- FTFT N/A
- Revenue
- RNAZ N/A
- FTFT $18,543,659.00
- Revenue This Year
- RNAZ N/A
- FTFT N/A
- Revenue Next Year
- RNAZ N/A
- FTFT N/A
- P/E Ratio
- RNAZ N/A
- FTFT N/A
- Revenue Growth
- RNAZ N/A
- FTFT N/A
- 52 Week Low
- RNAZ $2.66
- FTFT $0.23
- 52 Week High
- RNAZ $66.33
- FTFT $1.28
- Technical
- Relative Strength Index (RSI)
- RNAZ 48.31
- FTFT 40.48
- Support Level
- RNAZ $10.02
- FTFT $0.23
- Resistance Level
- RNAZ $11.30
- FTFT $0.28
- Average True Range (ATR)
- RNAZ 1.97
- FTFT 0.02
- MACD
- RNAZ -0.18
- FTFT 0.00
- Stochastic Oscillator
- RNAZ 26.75
- FTFT 13.20
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.